ABSTRACT
The upsurge of the severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) has turned into a global health disaster. Many remodeled medications were suggested for treatment in the early stages of this pandemic, but these dosages afterward came across with distinct offshoots. Thus, these consequences compelled the scientists to develop new drugs using various antiviral, antiinflammatory, antibacterial, and phytochemical compounds. A handful of drugs have been scrutinized in silico, in vitro, plus through human trials such as anti-SARS-CoV-2 agents and made available as various databases by various scientific communities. The SARS-CoV-2 pandemic databases are designed to allay difficulties associated with this scenario. Some of the popular databases are GESS (global evaluation of SARS-CoV-2/HCoV-19 sequences) which gives a thorough study of data based on tenfold of thousands of complete coverage and quality of SARS-CoV-2 genomes, CORona Drug InTERactions (CORDITE) database for SARS-CoV-2 which profoundly combines the understanding of potential drugs and make it available for scientists and medicos. SARSCOVIDB set one’s sights to merge all differential gene expression data, at mRNA and protein levels, helping to accelerate analysis and research on the molecular impact of covid-19. This chapter aims to provide a piece of complete information about the SARS-CoV-2 virus databases, potentially available drugs, and virtual screening methods. And also provides a different webserver to reach out for information related to the COVID-19 pandemic and its future. © 2022 Elsevier Inc. All rights reserved.
ABSTRACT
The outbreak and rapid spread of novel Coronavirus SARS-CoV-2 has resulted in global pandemic. The purpose of this work is to provide an ethnopharmacological overview of selected medicinal plants having antiviral activity along with their applications to treat COVID-19 related symptoms based on fragmented literature. Hundreds of published research articles were screened and reviewed using online search engines such as PubMed, PMC and Google Scholar with relevant keywords related to coronavirus, antiviral medicinal plants, phytochemical compounds, cough and fever. A total of 12 plants having antiviral activity against a number of viruses were documented with their probable mechanism of action. Most of the studied plants and their compounds were also reported to have other therapeutic potentials and were used to boost immunity, treat cough, fever, tiredness, difficulty in breathing and diarrhoea, which are common symptoms of COVID-19 infections as per World Health Organization. This review hopefully opens a new horizon in the development of antiviral drug against novel coronavirus COVID-19.
ABSTRACT
Introduction: The SARS-CoV2 pandemic impacted numerous aspects of medical practice, including continuingmedical education. In-person and single-institution educational formats could not address the challenges of socialdistancing, heterogeneous regional experiences, and continuously emerging data. The vulnerability of cancerpatients to SARS-CoV2 added further urgency to overcoming these barriers. To fulfill these unmet educational andpatient care needs, we established a novel cross-institutional trainee-driven, on-line collaborative for the purpose ofgenerating multidisciplinary seminars on emerging best practices for the acute management of patients with SARS-CoV2. Methods: The COVID Learning Initiative is currently managed by clinical trainees and faculty from 13 institutionsacross 10 states. Weekly Zoom conferences were led by a rotating team consisting of 2-3 fellows overseen by 4-5expert faculty from throughout the country. Format consisted of two 15-minute instructional segments presented bytrainees, followed by a concluding 30-minute faculty Q&A panel moderated by a trainee. Attendees completedbaseline demographics, SARS-CoV2 experience surveys, and pre/post conference knowledge questions.Conferences were recorded and archived to enhance access and dissemination of knowledge. Results: Within 6 weeks and beginning just 2 weeks after inception we produced five 1-hour-longmultidisciplinary video conferences covering emerging antiviral therapies, coagulopathy, pulmonary complications, provider resilience, and ethics of resource scarcity. On average, there were 100 participants per seminar. Post-conference questioning consistently demonstrated acquisition of knowledge across topics and disciplines. Attendeesalso improved in their self-assessed comfort managing multidisciplinary aspects of SARS-CoV2. Overall, presentingcollaborations involved 11 fellows and 28 faculty representing 6 medical specialties and 17 institutions. Severalcollaborations persisted, resulting in further dissemination of knowledge with tangible outcomes such as generationof peer-reviewed manuscripts. Conclusions: The COVID Learning Initiative demonstrated a novel continuing medical education platform capableof rapidly disseminating knowledge at a national scale, while realizing new opportunities for remote traineementoring and skills development. With initial feasibility and continued interest among participating institutions, COVID Learning Initiative plans to evolve to Fellows ACHIEVE: Alliance for Collaborative Hematology OncologyInter-Institutional Education through Videoconferencing to conduct an extended multi-institutional educational serieson adapting cancer management and training program best practices.